A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Trial Profile

A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs DUR 928 (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors DURECT Corporation
  • Most Recent Events

    • 26 Feb 2018 According to a DURECT Corporation media release, the company has commenced patient dosing in this trial at California Pacific Medical Center. Data anticipated in 2018.
    • 20 Feb 2018 According to a DURECT Corporation medis release, review on this trial will be presented in a Webcast on February 26 2018 at 12:00 p.m.
    • 08 Jan 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top